Life sciences

The life sciences sector encompasses companies in the fields of pharmaceuticals, biotechnology and medical technology that focus on the research, development and commercialisation of a wide range of products that have a medical application. Such products include pharmaceuticals (ie everything from over-the-counter painkillers to advanced therapies for treating diseases such as cancer or HIV), medical devices (eg plasters, syringes, heart stents, pacemakers, etc) and diagnostics.

Understandably, the life sciences sector is highly regulated and the development and commercialisation of products in the life sciences sector is subject to stringent rules. However, there is not one clearly defined body of ‘pharmaceutical’ or ‘life sciences’ law, instead, a complex framework of rules exists that derives from a variety of sources. In the EU, a large amount of the regulation originates from directives or regulations and is supplemented by guidance issued by the European Commission and by the European Medicines Agency (EMA), the decentralised agency of the EU responsible for the scientific evaluation, supervision and safety monitoring of medicines.

Trackers

Practice Notes: Life sciences tracker—EU and Life sciences cases tracker—EU are intended to be used to track the progress of

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest EU Law News

European Commission publishes 2025 State of the Digital Decade report

The European Commission has published its 2025 State of the Digital Decade report, urging renewed action on digital transformation and technological sovereignty. The report evaluates the EU's progress toward its 2030 digital transformation targets by examining four areas: digital infrastructure, business digitalisation, digital skills, and public service digitalisation. It reveals that while some progress has been made, the rollout of connectivity infrastructure such as fibre and 5G stand-alone networks remains slow. There is an increasing uptake of AI, cloud, and big data by companies, yet more rapid progress is essential. Furthermore, only just over half of Europeans have basic digital skills, and there is a shortage of advanced ICT specialists, a situation worsened by a significant gender imbalance which restricts progress in key sectors like cybersecurity and AI. Although the digitalisation of public services has made headway, a considerable portion of governmental digital infrastructure continues to rely on providers from outside the EU. Persistent challenges such as fragmented markets, complex regulations and strategic dependence call for greater public and private investment, reforms to better integrate the single market, and eased administrative burdens. These measures could potentially boost the EU's gross domestic product by an estimated 1.8% by 2030. Member States are set to review the recommendations and discuss the future course of action, with further assessments scheduled for 2026 to ensure that targets remain in line with the evolving digital landscape and the EU's broader ambitions.

View EU Law by content type :

Popular documents